Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101.8 PLN | +0.20% | +0.79% | +6.15% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.72 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.15% | 503M | - | ||
+14.70% | 65.04B | A- | ||
-1.61% | 47.76B | A- | ||
+14.58% | 40.72B | B+ | ||
+20.84% | 26.88B | A- | ||
+1.16% | 17.53B | B+ | ||
-21.87% | 16.03B | A- | ||
+1.11% | 15.17B | B+ | ||
-11.34% | 15.06B | C+ | ||
-20.82% | 13.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PCR Stock
- Ratings PCC Rokita SA